Tags

Type your tag names separated by a space and hit enter

Phosphate binders in CKD: chalking out the differences.
Pediatr Nephrol. 2010 Mar; 25(3):385-94.PN

Abstract

Plasma phosphate levels are important in the evolution of hyperparathyroidism and ectopic calcification in chronic kidney disease (CKD). Although dietary management may be adequate to control plasma phosphate in its early stages, most patients develop hyperphosphataemia by CKD stages 3-4 and require the addition of a phosphate binder. Calcium-containing phosphate binders are the most used and cheapest binders but have fallen out of favour because of the potential for positive calcium balance and calcium toxicity. This problem may be attenuated by newer phosphate binders such as sevelamer hydrochloride and lanthanum carbonate. In this review, the role of phosphate as a uraemic toxin and the advantages and disadvantages of the currently available phosphate binders are discussed.

Authors+Show Affiliations

Department of Nephrology, Great Ormond Street Hospital for Children NHS Trust, London, UK. Reesl@gosh.nhs.ukNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

19898877

Citation

Rees, Lesley, and Rukshana C. Shroff. "Phosphate Binders in CKD: Chalking Out the Differences." Pediatric Nephrology (Berlin, Germany), vol. 25, no. 3, 2010, pp. 385-94.
Rees L, Shroff RC. Phosphate binders in CKD: chalking out the differences. Pediatr Nephrol. 2010;25(3):385-94.
Rees, L., & Shroff, R. C. (2010). Phosphate binders in CKD: chalking out the differences. Pediatric Nephrology (Berlin, Germany), 25(3), 385-94. https://doi.org/10.1007/s00467-009-1329-0
Rees L, Shroff RC. Phosphate Binders in CKD: Chalking Out the Differences. Pediatr Nephrol. 2010;25(3):385-94. PubMed PMID: 19898877.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Phosphate binders in CKD: chalking out the differences. AU - Rees,Lesley, AU - Shroff,Rukshana C, Y1 - 2009/11/07/ PY - 2009/07/16/received PY - 2009/08/18/accepted PY - 2009/08/15/revised PY - 2009/11/10/entrez PY - 2009/11/10/pubmed PY - 2010/4/3/medline SP - 385 EP - 94 JF - Pediatric nephrology (Berlin, Germany) JO - Pediatr Nephrol VL - 25 IS - 3 N2 - Plasma phosphate levels are important in the evolution of hyperparathyroidism and ectopic calcification in chronic kidney disease (CKD). Although dietary management may be adequate to control plasma phosphate in its early stages, most patients develop hyperphosphataemia by CKD stages 3-4 and require the addition of a phosphate binder. Calcium-containing phosphate binders are the most used and cheapest binders but have fallen out of favour because of the potential for positive calcium balance and calcium toxicity. This problem may be attenuated by newer phosphate binders such as sevelamer hydrochloride and lanthanum carbonate. In this review, the role of phosphate as a uraemic toxin and the advantages and disadvantages of the currently available phosphate binders are discussed. SN - 1432-198X UR - https://www.unboundmedicine.com/medline/citation/19898877/Phosphate_binders_in_CKD:_chalking_out_the_differences_ L2 - https://dx.doi.org/10.1007/s00467-009-1329-0 DB - PRIME DP - Unbound Medicine ER -